Tesla
Dividend Schedule
Ranking of Stocks
Ranking of Brazilian ETFs
Crypto Rankings
See Graham's ranking
5.0
Abbott Laboratories operates in the Health Care sector, within the Medical Devices and Diagnostics industry. Founded in 1888 by Wallace Calvin Abbott, the company began with the goal of producing standardized pharmaceutical formulations based on scientific methods and quality control.
Today, Abbott maintains a diversified healthcare portfolio spanning diagnostics, medical devices, nutrition, and branded generic pharmaceuticals.
Its core divisions include:
-
Diagnostics.
-
Medical Devices.
-
Nutrition.
-
Established Pharmaceuticals.
Key products and solutions include:
-
Clinical laboratory and molecular diagnostic systems.
-
Rapid and point-of-care testing technologies.
-
Continuous glucose monitoring (CGM) systems.
-
Cardiovascular and structural heart devices.
-
Pediatric and adult nutritional products.
Abbott operates in more than 160 countries, supported by manufacturing facilities, research centers, and global distribution networks. Its customer base includes hospitals, laboratories, physicians, healthcare systems, and patients.
Performance is influenced by healthcare regulation, reimbursement policies, demographic trends such as population aging, chronic disease prevalence, innovation cycles, and competition within the global medical technology market.
Abbott shares trade on the New York Stock Exchange (NYSE) under the ticker ABT.
History and Development
Abbott was founded in 1888 in Chicago, where Wallace C. Abbott developed standardized drug formulations derived from medicinal plant extracts.
Throughout the 20th century, the company expanded beyond pharmaceuticals into diagnostics and medical devices, building research capabilities and international operations.
Over time, Abbott diversified through acquisitions and internal innovation, strengthening its presence in cardiovascular devices, diabetes care, and laboratory diagnostics.
A major milestone in recent years was the acquisition of St. Jude Medical, which expanded Abbott’s cardiovascular portfolio. The company also advanced its continuous glucose monitoring systems, positioning itself as a key player in diabetes management.
In recent years, Abbott has increased investment in rapid testing technologies, cardiovascular innovation, and global manufacturing capacity, reinforcing its position as a diversified medical technology company with broad international reach.
Additional Information
Abbott Laboratories (United States) is listed on the NYSE and has a market capitalization of $171.16 billion, with shareholders equity totaling $51.11 billion.
The company employs approximately 107.000 people and operates in the Health sector, within the Medical Supplies and Equipment industry.
Over the past 12 months, Abbott Laboratories reported $46.59 billion in revenue, generating net income of $5.43 billion.
Key financial metrics include a P/E ratio of 31.55, a price-to-book (P/B) ratio of 3.35, and a trailing twelve-month dividend yield of 2.53%.
The company trades under the ticker ABT.
